# OnCo record nct07024706 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct07024706/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct07024706", "NCT07024706" ;
  schema:name "Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab"@en ;
  schema:alternateName "MAVRiC"@en ;
  schema:description "A phase 2 trial of Acalabrutinib and Venetoclax in chronic lymphocytic leukaemia, run by AstraZeneca, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct07024706/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07024706> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2026-06-04" ;
  onco:cancers <https://onco.cc/cancers/cll/> ;
  onco:technologies <https://onco.cc/technologies/bcl2-inhibitors/>, <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/acalabrutinib/>, <https://onco.cc/drugs/venetoclax/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/>, <https://onco.cc/companies/abbvie/>, <https://onco.cc/companies/flatiron-health/> .